German pharmaceutical company BioNTech(BNTXhorizonforbiddenwestcrashing.US) continued to rise, up 6.5horizonforbiddenwestcrashing.36%, quoted at $97.9. On the news front. BioNTech will present important presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetinghorizonforbiddenwestcrashingclinical trial updates to showcase its multiple immuno-oncology product lineshorizonforbiddenwestcrashingAdvances in human rights, including innovative treatments for various cancers. The company's ambitious goal is to launch its first cancer immunotherapy by 2026 and gain approval for 10 cancer indications by 2030, a promising development for patients and investors.